A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Recruiting now

Conditions studied: Biliary Tract Cancer

In brief

The primary purpose of this study is to investigate the safety of Tasfygo.

Key facts

Study ID

NCT06793709

Run by

Eisai Co., Ltd.

People needed

60

Starts

2025-07-10

Expected to finish

2032-11-20

Last updated by the study team

2026-02-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.

You may not qualify if…

• Not applicable.

Where it is running

• #Eisai Trial Site 1 — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.